Hepatitis B virus surface antigen mutants persist in chronic carriers receiving lamivudine therapy in Singapore [4]

Journal of Antimicrobial Chemotherapy

Volumn 49, Issue 6, 2002, Pages 1044-1046

  Chen, Wei Ning ^a   Oon, Chong Jin ^a   Lim, Gek Keow ^a  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

DNA POLYMERASE; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; VIRUS DNA;

CLINICAL ARTICLE; CONTROLLED STUDY; GENETIC CODE; HEPATITIS B; HUMAN; LETTER; MUTATIONAL ANALYSIS; REBOUND; SEQUENCE ANALYSIS; SINGAPORE; VIRUS CARRIER; VIRUS MUTANT; VIRUS MUTATION; DRUG EFFECT; GENETICS; HETEROZYGOTE; IMMUNOLOGY; MUTATION; VIROLOGY;

CARRIER STATE; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B, CHRONIC; HUMAN; LAMIVUDINE; MUTATION; SINGAPORE; SUPPORT, NON-U.S. GOV'T; HUMANS;

EID: 0035992187     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (7)

1. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B
2. Molecular anatomy and pathophysiologic implications of drug resistance in hepatitis B virus infection
3. Human hepatitis B virus mutants: Significance of molecular changes
4. Hepatitis B virus variants with lamivudine-related mutations in the DNA polymerase and the 'a' epitope of the surface antigen are sensitive to ganciclovir
5. Changes in the antigenicity of a hepatitis B virus mutant stemming from lamivudine therapy
6. Altered antigenicities of hepatitis B virus surface antigen carrying mutations outside the common 'a' determinant
7. Genotypic succession of mutations of the hepatitis B virus polymerase associated with lamivudine resistance